ClinicalTrials.gg
TerminatedNCT05617885Updated Oct 15, 2026Results posted

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

A Phase 1 interventional study of Darolutamide and Abemaciclib in Metastatic Prostate Cancer, Non-metastatic Prostate Cancer and Prostate Cancer, sponsored by Praful Ravi, MB BCHir, MRCP. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Praful Ravi, MB BCHir, MRCP · Phase 1, Interventional, and Treatment

How we know · 11 judgments

Why this study was terminated
The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.
Updated Oct 15, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
56th of 59
9 · median 80
Started
2023
with 8 others
Phase 1
9 of 59
2 open now
Registered
31st of 59
by date

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 56th largest by enrollment, is one of 9 that started in 2023, is one of 9 in phase 1, and was the 31st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. The first phase of the study is to establish a recommended dose for the second phase.

The names of the study drugs and interventions involved in this study are:

  • Darolutamide
  • Abemaciclib
  • Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists

It is expected that about 93 people will take part in the research study.

Treatment is expected to last 6 months with a follow up period of up to 4.5 years.

Read the detailed description

This research study is a Phase I/II clinical trial to determine the safety and efficacy of the combination of abemaciclib and darolutamide with androgen deprivation therapy (ADT) in the treatment of metastatic and non-metastatic castration-resistance prostate cancer (CRPC) and for participants with high-risk, localized prostate cancer who will be undergoing radical prostatectomy (RP). A Phase I/II clinical trial tests the safety of investigational drugs with a lead-in phase and attempts to define the maximum tolerated dose of the investigational drugs to use for the second phase. "Investigational" means that the drugs are being studied together for the first time.

The names of the study drugs and interventions involved in this study are:

  • Darolutamide
  • Abemaciclib
  • Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) agonists, Leuprolide and Goserelin, and GnRH antagonist, Degarelix

In Phase I, participants will receive abemaciclib in combination with darolutamide and ADT at different dosages.

In Phase II, participants will be randomized into two groups of treatment: abemaciclib, darolutamide, and ADT versus darolutamide and ADT. Randomization means that participants are placed into one of the treatment groups by chance, like flipping a coin.

The U.S Food and Drug Administration (FDA) has approved androgen deprivation therapy as a treatment for prostate cancer. The FDA has not approved abemaciclib for prostate cancer but it has been approved for other uses. Abemaciclib is approved for use in advanced breast cancer. The FDA has approved darolutamide as a treatment option in men with non-metastatic CRPC but it is not approved in men with metastatic CRPC or localized prostate cancer. Research procedures include screening for eligibility, study treatment including evaluations, blood collection, and radiology scans of the prostate.

It is expected about 93 participants will take part in this research study.

Treatment is expected to last 6 months with a follow up period of up to 4.5 years.

Lilly is supporting this research study by providing funding and the study drug, abemaciclib. Bayer is supporting the study by providing the study drug, darolutamide.

The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.

03

Conditions studied

  • Metastatic Prostate Cancer
  • Non-metastatic Prostate Cancer
  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Hormone Therapy
  • Androgen Deprivation Therapy
  • Metastatic Prostate Cancer
  • Non-metastatic Prostate Cancer
  • Radical Prostatectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria For Phase 1:

  • Provision of signed prior to any study specific procedures, or have a legally authorized representative sign on the participant's behalf.
  • Ability to swallow oral medications and comply with study procedures and requirements.
  • Males ≥18 years
  • or cytologically confirmed adenocarcinoma of the prostate without histologic variants (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma) comprising >50% of the sample as determined by academic medical center pathology review; men without histologic confirmation are eligible provided there is unequivocal evidence of prostate cancer (eg. very high PSA) in the view of the treating physician.
  • M0 or M1 (by CT/MRI and bone scans) CRPC with evidence of progression at study entry demonstrated during continuous androgen deprivation therapy (LHRH/GnRH agonists/antagonists/post orchiectomy) and castrate level of serum testosterone (≤50 ng/dl). Progression is defined as one or more of the following:

    • Sequence of at least 2 rising PSA values at a minimum of 1-week intervals with the last result being at least 1.0 ng/mL if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen (flutamide, bicalutamide or nilutamide) must have PSA progression ≥4 weeks after the last dose.
    • Radiographic progression per 1.1 for soft tissue and/or per PCWG3 for bone (i.e., appearance of ≥2 new bone lesions), with or without PSA progression.
  • Serum testosterone level must be ≤50 ng/dL (1.73 nmol/L) at the screening visit. Participants who have not undergone bilateral orchiectomy are required to continue LHRH/GnRH agonists/antagonists) throughout the study.
  • performance status ≤2 ( ≥60%, see Appendix A).
  • Participants must have adequate organ and marrow function as below:

    • System Laboratory Value
    • Hematologic
    • ≥1.5×109/L
    • ≥100×109/L
    • ≥9g/dL (≥90g/L) independent of transfusions
    • Hepatic
    • Total ≤1.5 × OR \<2 × ULN if known or suspected Gilbert's syndrome
    • and AST ≤3 × ULN OR ≤5 × ULN if liver present
    • Renal
    • ≥30 mL/min/1.73 m2 (based on formula [Appendix D] OR 24 hour urine collection.
    • Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate; ULN = upper limit of normal.
  • The effects of darolutamide and abemaciclib on the developing human fetus are unknown. Participants and their partners must agree to use an effective method (hormonal or barrier method of birth control, or abstinence) during the study and for 3 weeks after the last dose of study treatment (darolutamide and/or abemaciclib) if engaged in sex with a woman of , and participants must not donate sperm during this period. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately.

Inclusion Criteria for Phase 2:

  • Provision of signed informed consent prior to any study specific procedures, or have a legally authorized representative sign on the participant's behalf.
  • Ability to swallow oral medications and comply with study procedures and requirements.
  • Males ≥18 years.
  • Histologically confirmed adenocarcinoma of the prostate without histologic variants (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma) comprising >50% of the sample as determined by academic medical center pathology review.
  • ≥3 cores (either systematic or targeted, or a combination) involved with prostate cancer. Prostate biopsy must have been performed within 6 months of screening. \<3 biopsy cores with cancer are allowed if the patient has >1cm of tumor or ≥cT3 disease on MRI prostate.
  • Participants must have at least 1 biopsy core with either:

    • Gleason ≥8 OR
    • Gleason 4+3=7 AND at least one of the following:

      • PSA >20ng/dL
      • ≥cT3 disease by MRI
      • Evidence of EPE on biopsy
  • No evidence of metastatic disease as determined by radionuclide bone scan and CT/MRI, and/or PSMA-PET. Pelvic lymph nodes \<2cm in short axis are permitted. If PSMA-PET does not show evidence of metastatic disease, CT/MRI and bone scan is not required.

Either PSMA-PET or CT/MRI abdomen and bone scan is required before C1D1. NOTE: participants with possible evidence of bone, nodal or visceral metastatic disease on PSMA-PET imaging at baseline (but not CT/MRI or bone scan) are eligible and their participation is encouraged. All participants treated at DFCI must undergo PSMA-PET at baseline or within 28 days of C1D1 (per institutional practice) and will also undergo a research-only PSMA-PET after completion of therapy and prior to RP.

  • Participants must be candidates for RP and be considered surgically resectable by a Urologist.
  • ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A).
  • Participants must have adequate organ and marrow function as defined below:

    • System Laboratory Value
    • Hematologic
    • ANC ≥1.5×109/L
    • Platelets ≥100×109/L
    • Hemoglobin≥9g/dL (≥90g/L) independent of transfusions
    • Hepatic
    • Total Bilirubin ≤1.5 × ULN, \<2 × ULN if known or suspected Gilbert's syndrome
    • ALT and AST ≤3 × ULN
    • Renal
    • eGFR ≥30 mL/min/1.73 m2 (based on Cockcroft-Gault formula [Appendix D] OR 24 hour urine collection.
    • Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate; ULN = upper limit of normal.
  • The effects of darolutamide and abemaciclib on the developing human fetus are unknown. Participants and their partners must agree to use an effective contraception method (hormonal or barrier method of birth control, or abstinence) during the study and for 3 weeks after the last dose of study treatment (darolutamide and/or abemaciclib) if engaged in sex with a woman of childbearing potential, and participants must not donate sperm during this period. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately.

Exclusion Criteria for Phase 1:

  • Participants who have had chemotherapy or radiotherapy within 4 weeks prior to planned cycle 1 day 1 of study treatment.
  • Participants who have received anti-neoplastic intervention or experimental antineoplastic therapy within 14 days of planned cycle 1 day 1 of study therapy.
  • Participants who are receiving any other agents.
  • Participants who have previously received darolutamide, abemaciclib or another CDK4/6 inhibitor.
  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e. have residual toxicities ≥Grade 2) with the exception of alopecia.
  • Any of the following within 6 months before planned cycle 1 day 1 of study therapy:

    • Stroke
    • Myocardial infarction
    • Severe/unstable angina pectoris
    • Coronary/peripheral artery bypass graft
    • Congestive heart failure (NYHA) Class III or IV.
  • Known or suspected , or allergy to darolutamide or abemaciclib or to any of their .
  • Participants with , or human immunodeficiency () who are on anti-viral therapy that has the potential to interact with darolutamide or abemaciclib.
  • Participants with untreated . Participants with treated brain metastases are eligible if follow-up brain imaging at least 4 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression and ongoing are not required. Participants with new or progressive brain metastases (active brain metastases) or are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
  • Participants treated with drugs known to be strong inhibitors and/or inducers of cytochrome P450 3A4 () and the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.

NOTE: precaution is warranted with concomitant use of agents with a narrow therapeutic index that are substrates of P-gp, BCRP and OCT1.

Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.

  • The participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance \<30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Concurrent active whose natural history or treatment has the potential to interfere with safety or efficacy assessment of the investigational regimen. Patients with non-melanomatous skin cancer, superficial bladder cancer, cancer not needing active therapy for at least 2 years, cancer for which the treating investigator deems the subject to be in remission, or any prior malignancy that was treated with curative intent (no evidence of disease for at least 3 years) are permitted to enroll.

Exclusion Criteria for Phase 2:

  • 3.4.1 Prior radiotherapy, bilateral orchiectomy, investigational therapy or systemic therapy (including LHRH/GnRH agonists/antagonists, anti-androgens, CYP17 inhibitors, AR antagonists) for prostate cancer. LHRH/GnRH agonists/antagonists are permitted if begun within 4 weeks of day 1; up to 4 weeks of bicalutamide is permitted if it is stopped 2 weeks prior to day 1. Prior therapy with 5-⍺-reductase inhibitors is allowed but must be stopped 2 weeks prior to day 1.
  • Hypogonadism or severe androgen deficiency as defined by screening serum testosterone \< 200ng/dL. Patients who have a low screening testosterone due to prior ADT (per 3.4.1) will still be allowed to enroll on study if they do not have a known history of hypogonadism or severe androgen deficiency.
  • Major surgery or radiotherapy within 4 weeks of start of treatment.
  • Any of the following within 6 months before randomization:

    • Stroke
    • Myocardial infarction
    • Severe/unstable angina pectoris
    • Coronary/peripheral artery bypass graft
    • Congestive heart failure New York Heart Association (NYHA) Class III or IV.
  • Known or suspected contraindications, hypersensitivity or allergy to darolutamide or abemaciclib or to any of their excipients.
  • Participants with hepatitis C, hepatitis B or human immunodeficiency (HIV) who are on anti-viral therapy that has the potential to interact with darolutamide or abemaciclib.
  • Patient treated with drugs known to be moderate or strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.

NOTE: precaution is warranted with concomitant use of agents with a narrow therapeutic index that are substrates of CYP3A4, P-gp, BCRP and OCT1.

Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.

  • The participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance \<30ml/min] or history of renal transplant, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Concurrent active malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of the investigational regimen. Patients with non-melanomatous skin cancer, superficial bladder cancer, cancer not needing active therapy for at least 2 years, cancer for which the treating investigator deems the subject to be in remission, or any prior malignancy that was treated with curative intent (no evidence of disease for at least 3 years) are permitted to enroll.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Phase 1 Lead In in CRPC

    Standard 3+3 dose escalation scheme with 3 dose levels of abemaciclib and a constant dose of darolutamide, per protocol, for 6, 28-day cycles

    Drug: Darolutamide · Drug: Abemaciclib · Drug: GNRH-A Leuprolide Acetate · Drug: GNRH-A Goserelin · Drug: Degarelix

  • Experimental
    Phase 2 - Neoadjuvant Darolutamide and ADT prior to Radical Prostatectomy

    per protocol, for 6, 28-day cycles

    Drug: Darolutamide · Drug: GNRH-A Leuprolide Acetate · Drug: GNRH-A Goserelin · Drug: Degarelix

  • Experimental
    Phase 2 - Neoadjuvant Darolutamide, Ademaciclib, and ADT prior to Radical Prostatectomy

    per protocol, for 6, 28-day cycles

    Drug: Darolutamide · Drug: Abemaciclib · Drug: GNRH-A Leuprolide Acetate · Drug: GNRH-A Goserelin · Drug: Degarelix

Interventions

  • Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.

    Also known as: Nubeqa

  • Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a "CDK4/6 inhibitor". CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing.

    Also known as: Verzenio

  • DrugLuprolide acetate gel depotStudies of Luprolide acetate gel depotLuprolide acetate gel depot pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.

    Also known as: Eligard, Lupron Depot, Lupron Depot-Ped

  • DrugGoserelinStudies of GoserelinGoserelin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.

    Also known as: Zoladex

  • Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.

    Also known as: Firmagon

06

What researchers measure

Primary outcomes

  1. Phase 1 - Number of Subjects With Dose Limiting Toxicity (DLT)

    Dose Limiting Toxicity (DLT) for Phase 1 will be defined as any abemaciclib or darolutamide-related toxicity resulting in discontinuation or dose reduction within the first 28 days of treatment, using NCI CTCAE criteria version 5.0. DLTs will be defined as any of the following events: * Any death * Dose delay of \>14 days for the study drug(s) due to an adverse event * Non-hematologic toxicity: * Grade 3 or higher * Hy's Law cases (AST or ALT \>3 x upper limit of normal (ULN) AND total bilirubin \>2 x ULN AND ALP \<2 x ULN AND no other reason for liver injury) * AST or ALT \>8 x ULN or AST or ALT \> 5 x ULN for ≥14 days regardless of the absence of presence of hepatic metastases * Hematologic toxicity: * Grade 4 that persists for more than 7 days * Grade 3 or higher thrombocytopenia with clinically significant bleeding * Febrile neutropenia

    Time frame: Within the first 28 days of treatment (Cycle 1)

  2. Phase 1 - Maximum Tolerated Dose (MTD) of Abemaciclib

    The Maximum Tolerated Dose (MTD) for the study drug is defined as the maximum dose combination at which \<33% of patients experience a Dose limiting toxicity (DLT) during Cycle 1 (the DLT-evaluation period). If a DLT is observed in 1 of 3 patients, then 3 additional patients will be enrolled at that same dose level. Dose escalation will continue to a dose of abemaciclib 200mg bid, which is the maximal dose levels. If DLTs are seen in 0-1 of 6 patients at dose level +1 (darolutamide 600mg bid and abemaciclib 200mg bid), then this will be the RP2D; otherwise the maximally tolerated dose (MTD) will be the RP2D.

    Time frame: Within the first 28 days of treatment (Cycle 1)

  3. Phase 1 - Recommended Phase 2 Dose (RP2D) for Abemaciclib

    RP2D will be determined after a Maximum Tolerated Dose (MTD) is identified or the maximum planned dose is achieved. RP2D is defined as no more than 0-1 patients with dose limiting toxicity during cycle 1, out of 6 at maximal dose level. Otherwise, the maximally tolerated dose will be used.

    Time frame: Within the first 28 days of treatment (Cycle 1)

  4. Phase 2 - Pathological Response Rate

    Pathologic response is defined as achieving either a complete response (pCR) or minimal residual disease (MRD, defined as ≤5mm residual tumor) at Radical Prostatectomy (RP) in both arms

    Time frame: Disease evaluated from baseline to Pre-Radical Prostatectomy (RP), up to 6 months

Secondary outcomes

  1. Phase 1 - Objective Response Rate (ORR)

    The objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

    Time frame: Disease evaluated every 12 weeks, up to 6 months

  2. Phase 1 - Radiographic Progression-Free Survival (rPFS) at 6 Months

    Radiographic Progression-Free Survival (rPFS) is defined as the time from protocol treatment initiation to the earlier of progression by PCWG3 criteria or death due to any cause. PCWG3 progression is defined as when it is felt by the treating physician that the patient is "no longer clinically benefiting" (NLCB) from therapy. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. rPFS at 6 months will be evaluated by the Kaplan Meier methodology.

    Time frame: Evaluated every 12 weeks, up to 6 months

  3. Phase 1 - Grade 3 or Higher Treatment-Related Toxicity Rate

    Defined as all grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

    Time frame: From study treatment initiation until within 30 days of the last dose of treatment, up to 6.5 months

  4. Phase 2 - Frequency of Certain Adverse Event (AE)

    Certain Adverse Event (AE) includes frequency of positive surgical margins, extracapsular extension, seminal vesicle invasion and lymph node positivity.

    Time frame: 28 days, up to 6 months

  5. Phase 2 - Change in Prostate Specific Antigen (PSA)

    A prostate-specific antigen (PSA) test is a blood test that measures the level of PSA in a sample of blood. PSA test will be done by local institutional labs and reported as nanograms of PSA per milliliter (ng/mL) of blood

    Time frame: PSA is measured day 1 of each cycle, up to 6 months. Each cycle is 28 days.

  6. Phase 2 - 3-year Biochemical Progression-free Survival (bPFS) Rate

    3-year bPFS rate is the proportion of participants remaining alive and free of biochemical progression at 3 years. Biochemical progression is defined as a PSA rising to \>0.1ng/mL after surgery.

    Time frame: At 3 years post radical prostatectomy

  7. Phase 2 - 5-year Progression-free Survival (bPFS) Rate

    5-year bPFS rate is the proportion of participants remaining alive and free of biochemical progression at 5 years. Biochemical progression is defined as a PSA rising to \>0.1ng/mL after surgery.

    Time frame: At 5 years post radical prostatectomy,

  8. Phase 2 - Proportion Free From Prostate Cancer Therapy

    Proportion free from further prostate cancer therapy will be estimated from the Kaplan Meier methodology by each arm. Further prostate cancer therapy includes salvage radiotherapy and/or ADT.

    Time frame: at 2, 3, and 5 years post radical prostatectomy

07

Results

Posted Oct 15, 2026

Participant flow

9 subjects have been enrolled in the phase I portion of the study.

Participant flow — Overall Study
MilestonePhase I Dose Level 0Phase I Dose Level -1
Started36
Completed00
Not completed36
Withdrew: Radiographic progression21
Withdrew: Physician decision02
Withdrew: Adverse event01
Withdrew: Still on therapy12

Outcome measures

PrimaryPhase 1 - Number of Subjects With Dose Limiting Toxicity (DLT)

Dose Limiting Toxicity (DLT) for Phase 1 will be defined as any abemaciclib or darolutamide-related toxicity resulting in discontinuation or dose reduction within the first 28 days of treatment, using NCI CTCAE criteria version 5.0. DLTs will be defined as any of the following events: * Any death * Dose delay of \>14 days for the study drug(s) due to an adverse event * Non-hematologic toxicity: * Grade 3 or higher * Hy's Law cases (AST or ALT \>3 x upper limit of normal (ULN) AND total bilirubin \>2 x ULN AND ALP \<2 x ULN AND no other reason for liver injury) * AST or ALT \>8 x ULN or AST or ALT \> 5 x ULN for ≥14 days regardless of the absence of presence of hepatic metastases * Hematologic toxicity: * Grade 4 that persists for more than 7 days * Grade 3 or higher thrombocytopenia with clinically significant bleeding * Febrile neutropenia

Time frame:
Within the first 28 days of treatment (Cycle 1)
Reported as:
Count of participants · Participants
Phase 1 - Number of Subjects With Dose Limiting Toxicity (DLT)
ParticipantsPhase I Dose Level 0Phase I Dose Level -1
Phase 1 - Number of Subjects With Dose Limiting Toxicity (DLT)20
PrimaryPhase 1 - Maximum Tolerated Dose (MTD) of Abemaciclib

The Maximum Tolerated Dose (MTD) for the study drug is defined as the maximum dose combination at which \<33% of patients experience a Dose limiting toxicity (DLT) during Cycle 1 (the DLT-evaluation period). If a DLT is observed in 1 of 3 patients, then 3 additional patients will be enrolled at that same dose level. Dose escalation will continue to a dose of abemaciclib 200mg bid, which is the maximal dose levels. If DLTs are seen in 0-1 of 6 patients at dose level +1 (darolutamide 600mg bid and abemaciclib 200mg bid), then this will be the RP2D; otherwise the maximally tolerated dose (MTD) will be the RP2D.

Time frame:
Within the first 28 days of treatment (Cycle 1)
Reported as:
Number · mg
Phase 1 - Maximum Tolerated Dose (MTD) of Abemaciclib
mgPhase I Overall (Dose Level 0 & Level -1 Combined)
Phase 1 - Maximum Tolerated Dose (MTD) of Abemaciclib100
PrimaryPhase 1 - Recommended Phase 2 Dose (RP2D) for Abemaciclib

RP2D will be determined after a Maximum Tolerated Dose (MTD) is identified or the maximum planned dose is achieved. RP2D is defined as no more than 0-1 patients with dose limiting toxicity during cycle 1, out of 6 at maximal dose level. Otherwise, the maximally tolerated dose will be used.

Time frame:
Within the first 28 days of treatment (Cycle 1)
Reported as:
Number · mg
Phase 1 - Recommended Phase 2 Dose (RP2D) for Abemaciclib
mgPhase I Overall (Dose Level 0 & Level -1 Combined)
Phase 1 - Recommended Phase 2 Dose (RP2D) for Abemaciclib100
PrimaryPhase 2 - Pathological Response Rate

Pathologic response is defined as achieving either a complete response (pCR) or minimal residual disease (MRD, defined as ≤5mm residual tumor) at Radical Prostatectomy (RP) in both arms

Time frame:
Disease evaluated from baseline to Pre-Radical Prostatectomy (RP), up to 6 months

No measurements were reported for this outcome.

SecondaryPhase 1 - Objective Response Rate (ORR)

The objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

Time frame:
Disease evaluated every 12 weeks, up to 6 months
Reported as:
Count of participants · Participants
Phase 1 - Objective Response Rate (ORR)
ParticipantsPhase I Dose Level 0Phase I Dose Level -1
Phase 1 - Objective Response Rate (ORR)00
SecondaryPhase 1 - Radiographic Progression-Free Survival (rPFS) at 6 Months

Radiographic Progression-Free Survival (rPFS) is defined as the time from protocol treatment initiation to the earlier of progression by PCWG3 criteria or death due to any cause. PCWG3 progression is defined as when it is felt by the treating physician that the patient is "no longer clinically benefiting" (NLCB) from therapy. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. rPFS at 6 months will be evaluated by the Kaplan Meier methodology.

Time frame:
Evaluated every 12 weeks, up to 6 months
Reported as:
Number · Percentage
Phase 1 - Radiographic Progression-Free Survival (rPFS) at 6 Months
PercentagePhase I Dose Level 0Phase I Dose Level -1
Phase 1 - Radiographic Progression-Free Survival (rPFS) at 6 Months33 (1 to 77)80 (20 to 97)
SecondaryPhase 1 - Grade 3 or Higher Treatment-Related Toxicity Rate

Defined as all grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

Time frame:
From study treatment initiation until within 30 days of the last dose of treatment, up to 6.5 months
Reported as:
Count of participants · Participants
Phase 1 - Grade 3 or Higher Treatment-Related Toxicity Rate
ParticipantsPhase I Dose Level 0Phase I Dose Level -1
Phase 1 - Grade 3 or Higher Treatment-Related Toxicity Rate32
SecondaryPhase 2 - Frequency of Certain Adverse Event (AE)

Certain Adverse Event (AE) includes frequency of positive surgical margins, extracapsular extension, seminal vesicle invasion and lymph node positivity.

Time frame:
28 days, up to 6 months

No measurements were reported for this outcome.

SecondaryPhase 2 - Change in Prostate Specific Antigen (PSA)

A prostate-specific antigen (PSA) test is a blood test that measures the level of PSA in a sample of blood. PSA test will be done by local institutional labs and reported as nanograms of PSA per milliliter (ng/mL) of blood

Time frame:
PSA is measured day 1 of each cycle, up to 6 months. Each cycle is 28 days.

No measurements were reported for this outcome.

SecondaryPhase 2 - 3-year Biochemical Progression-free Survival (bPFS) Rate

3-year bPFS rate is the proportion of participants remaining alive and free of biochemical progression at 3 years. Biochemical progression is defined as a PSA rising to \>0.1ng/mL after surgery.

Time frame:
At 3 years post radical prostatectomy

No measurements were reported for this outcome.

SecondaryPhase 2 - 5-year Progression-free Survival (bPFS) Rate

5-year bPFS rate is the proportion of participants remaining alive and free of biochemical progression at 5 years. Biochemical progression is defined as a PSA rising to \>0.1ng/mL after surgery.

Time frame:
At 5 years post radical prostatectomy,

No measurements were reported for this outcome.

SecondaryPhase 2 - Proportion Free From Prostate Cancer Therapy

Proportion free from further prostate cancer therapy will be estimated from the Kaplan Meier methodology by each arm. Further prostate cancer therapy includes salvage radiotherapy and/or ADT.

Time frame:
at 2, 3, and 5 years post radical prostatectomy

No measurements were reported for this outcome.

Adverse events

Collected over From study treatment initiation until within 30 days of the last dose of treatment, up to 6.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I Dose Level 01/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase I Dose Level -10/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPhase I Dose Level 0Phase I Dose Level -1
Bone infectionInfections and infestations1/30/6
StrokeNervous system disorders0/31/6
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPhase I Dose Level 0Phase I Dose Level -1
Creatinine increasedInvestigations3/33/6
Neutrophil count decreasedInvestigations3/33/6
AnemiaBlood and lymphatic system disorders2/34/6
VomitingGastrointestinal disorders2/30/6
DiarrheaGastrointestinal disorders1/33/6
Alanine aminotransferase increasedInvestigations0/33/6
FatigueGeneral disorders1/32/6
Aspartate aminotransferase increasedInvestigations1/32/6
Back painMusculoskeletal and connective tissue disorders1/32/6
COVID-19Infections and infestations1/31/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase I Dose Level 0Phase I Dose Level -1Total
Median74 (66 to 74)69 (54 to 80)70 (54 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Dose Level 0Phase I Dose Level -1Total
Female000
Male369
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I Dose Level 0Phase I Dose Level -1Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White369
More than one race000
Unknown or Not Reported000
Prostate-Specific Antigen level (ng/ML)
Prostate-Specific Antigen level (ng/ML)(ng/ML)Phase I Dose Level 0Phase I Dose Level -1Total
Median95 (30 to 154)10 (1 to 216)31 (1 to 216)
08

Study locations

1 site
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jul 2025, 23 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 16, 2022
StartActual
Aug 9, 2023
Primary completionActual
Jul 15, 2025
CompletionActual
Jun 1, 2026
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.
changed Oct 15, 2026
Results
Results posted
posted Oct 15, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedPhase 1 - Maximum ToleratedNumber of Subjects With Dose Limiting Toxicity (MTDDLT)Time frame: 28 days/Cycle 1, up to 6 months → Within the first 28 days of treatment (Cycle 1)
  • EditedPhase 1 - Maximum Tolerated Dose Limiting Toxicity (DLT)(MTD) of AbemaciclibTime frame: 28 days/Cycle 1, up to 6 months → Within the first 28 days of treatment (Cycle 1)
  • EditedPhase 1 - Recommended Phase 2 Dose (RP2D) for AbemaciclibTime frame: 28 days/Cycle 1, up to 6 months → Within the first 28 days of treatment (Cycle 1)
Oct 15, 2026
Documents
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedPhase 1 - Median Radiographic Progression-Free Survival (rPFS) at 6 MonthsTime frame: Evaluated every 12 weeks, up to 6 months
  • EditedPhase 1 & 2 - Grade 3 or Higher Treatment-Related Toxicity RateTime frame: 28 days, up to 6 months → From study treatment initiation until within 30 days of the last dose of treatment, up to 6.5 months
  • EditedPhase 2 - 3-year biochemical progressionBiochemical Progression-free survivalSurvival (bPFS) RateTime frame: at 3 years → At 3 years post radical prostatectomy
  • EditedPhase 2 - 5-year progressionProgression-free survivalSurvival (bPFS) RateTime frame: at 5 years → At 5 years post radical prostatectomy,
  • EditedPhase 2 - Proportion free fromFree From Prostate Cancer TherapyTime frame: at 2, 3, and 5 years. → at 2, 3, and 5 years post radical prostatectomy
Oct 15, 2026
Sponsor
Collaborators added: National Cancer Institute (NCI)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Completed→Terminated
    Why stopped The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.
    Results posted
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedPhase 1 - Maximum ToleratedNumber of Subjects With Dose Limiting Toxicity (MTDDLT)Time frame: 28 days/Cycle 1, up to 6 months → Within the first 28 days of treatment (Cycle 1)
    • EditedPhase 1 - Maximum Tolerated Dose Limiting Toxicity (DLT)(MTD) of AbemaciclibTime frame: 28 days/Cycle 1, up to 6 months → Within the first 28 days of treatment (Cycle 1)
    • EditedPhase 1 - Recommended Phase 2 Dose (RP2D) for AbemaciclibTime frame: 28 days/Cycle 1, up to 6 months → Within the first 28 days of treatment (Cycle 1)
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedPhase 1 - Median Radiographic Progression-Free Survival (rPFS) at 6 MonthsTime frame: Evaluated every 12 weeks, up to 6 months
    • EditedPhase 1 & 2 - Grade 3 or Higher Treatment-Related Toxicity RateTime frame: 28 days, up to 6 months → From study treatment initiation until within 30 days of the last dose of treatment, up to 6.5 months
    • EditedPhase 2 - 3-year biochemical progressionBiochemical Progression-free survivalSurvival (bPFS) RateTime frame: at 3 years → At 3 years post radical prostatectomy
    • EditedPhase 2 - 5-year progressionProgression-free survivalSurvival (bPFS) RateTime frame: at 5 years → At 5 years post radical prostatectomy,
    • EditedPhase 2 - Proportion free fromFree From Prostate Cancer TherapyTime frame: at 2, 3, and 5 years. → at 2, 3, and 5 years post radical prostatectomy
    Sponsor Collaborators added: National Cancer Institute (NCI)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05617885
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Responsible party
Praful Ravi, MB BCHir, MRCP (Principal Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Nov 16, 2022
Start date
Aug 9, 2023
Primary completion
Jul 15, 2025
Completion
Jun 1, 2026
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Praful Ravi, MB BChir, MRCP
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Abemaciclib

Start the discussion